1.Correlation analysis between the exposure levels and the serum protein fingerprints in population exposure to silica.
Hai-xia KONG ; Wei LIU ; Qing-bo MA ; Juan-juan CHEN ; Mao-ti WEI ; Shi-xin WANG ; Ya-guang WENG
Chinese Journal of Industrial Hygiene and Occupational Diseases 2012;30(4):258-260
OBJECTIVETo explore the correlation between the exposure levels and serum protein fingerprints in population exposed to silica.
METHODSLiquid chip time-of-flight mass spectrometry technology was used to investigate the serum profiles in control group (30 cases), group exposed to silica (30 cases), silicosis group (I stage, 25 cases) and suspected silicosis group (30 cases), and screen the differential expression proteins. The correlation between the levels of the differential expression proteins and the exposure levels was performed.
RESULTSFive differential expression proteins were found among 4 groups, the expression of 5081 and 5066 proteins was upregulated, and the expression of 3954, 2021 and 1777 proteins was downregulated. There was no the correlation between the exposure levels and the peak with M/Z among those proteins.
CONCLUSIONthe results of present investigation indicated there was no correlation between the exposure levels and protein/peptide peak.
Adult ; Blood Proteins ; analysis ; Case-Control Studies ; Dust ; analysis ; Female ; Humans ; Male ; Mass Spectrometry ; Middle Aged ; Occupational Exposure ; analysis ; Peptide Mapping ; Proteomics ; Silicon Dioxide ; toxicity ; Silicosis ; blood
2.The proteomics research on relational expressed serum proteins among the recovered SARS patients complicating avascular necrosis of femoral head.
Hong-Yan JIANG ; Shi-Xin WANG ; Xue-Hua LI ; Mao-Ti WEI ; Xia YANG ; Juan-Juan CHEN ; Da-Wei LUAN ; Zhe LI ; Yi-Hui CHEN ; Ya-Guang WENG
Chinese Journal of Preventive Medicine 2008;42(7):522-526
OBJECTIVETo seek differentially expressed serum proteins in recovered SARS patients complicating avascular necrosis of femoral head (AVNFH).
METHODS2-DE and MALDI-TOF MS were used to study the comparative serum proteomics among female SARS AVNFH group, female SARS non-AVNFH group and female healthy group. ELISA method was used to detect serum amyloid P component in individual serum; specificity and sensitivity of serum amyloid P component were analyzed.
RESULTSAverage protein points on 2-DE of 3 groups were 632 +/- 28, 671 +/- 55, 688 +/- 42 respectively, and the matching rate of protein points was ranged from 85% to 95%; eighteen differentially expressed proteins were discovered including transthyretin, serpin peptidase inhibitor, alpha-1-antitrypsin precursor, serum amyloid P components, etc. Compared to healthy group and SARS non-AVNFH group, transthyretin, C4B3, fibrinogen gamma, apolipoprotein L, apolipoprotein A-IV precursor, albumin and prealbumin showed lower expression, inversely serpin peptidase inhibitor, alpha-1-antitrypsin precursor and serum amyloid P components showed higher expression in serum in the SARS AVNFH necrosis group. The serum amyloid P component in 3 groups were 0.54 +/- 0.30 ng/ml, 0.83 +/- 0.39 ng/ml, 1.21 +/- 0.29 ng/ml respectively. The areas under the ROC curve on serum amyloid P component was 0.854, the specificity was 77.8% and the sensitivity was 85.2%.
CONCLUSIONThere were differentially expressed serum proteins in three groups. Serum amyloid P components might be one of the potential biomarkers in serum of recovered SARS patients complicating avascular necrosis of femoral head.
Adult ; Blood Proteins ; analysis ; Case-Control Studies ; Electrophoresis, Gel, Two-Dimensional ; Female ; Femur Head Necrosis ; blood ; etiology ; Humans ; Proteomics ; Severe Acute Respiratory Syndrome ; blood ; complications ; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
3.A retrospective controlled study of TACE-HAIC-targeted-immune quadruple therapy for intermediate and advanced-stage hepatocellular carcinoma.
Ling LI ; Jian HE ; Yi Xing XIE ; Xin Hui HUANG ; Xia Ti WENG ; Xin Ting PAN ; Yu Bing JIAO ; Hang Hai ZHENG ; Lin Bin QIU ; Wu Hua GUO
Chinese Journal of Hepatology 2022;30(9):939-946
Objective: To evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE)-hepatic arterial infusion chemotherapy (HAIC)-targeted-immune quadruple therapy in patients with intermediate and advanced-stage hepatocellular carcinoma (HCC). Methods: 101 patients with intermediate and advanced stage HCC were enrolled according to the inclusion and exclusion criteria, and then they were divided into a combination group and a control group. Patients in the combination group was treated with TACE-HAIC-targeted-immune quadruple therapy, while the control group was only treated with TACE therapy. The overall survival (OS), progression-free survival (PFS), and treatment-related adverse reactions were statistically analyzed in the two groups of patients. Statistical analysis was carried out by t-test, χ2 test, rank sum test, Kaplan-Meier curve, log-rank test, Cox regression (or proportional hazards model) analysis according to different data. Results: The tumor objective response rate and disease control rate as evaluated by mRECIST 1.1 criteria in the combination group were 80% and 94%, respectively, which were significantly higher than those in the control group, 41.2% (P<0.001) and 74.5% (P=0.007). The OS and PFS of the combination group were 15.6 months [95%CI 11.3-NA ] and 8.8 months [95%CI 6.9-12.0], respectively, which were significantly better than the control group at 6.1 months [95%CI 5.3-6.6] (P<0.001) and 3.2 months [95%CI 3.0-3.6] (P<0.001). Gastric ulcer incidence was significantly higher in the combination group (9/50, 18%) than that in the control group (2/51, 3.9%) (P=0.023). Conclusion TACE-HAIC-targeted-immune quadruple therapy is a more effective treatment mode for intermediate and advanced-stage HCC than TACE alone, and attention should be paid to the monitoring of target immune-related adverse reactions.
Humans
;
Carcinoma, Hepatocellular/pathology*
;
Chemoembolization, Therapeutic
;
Liver Neoplasms/pathology*
;
Retrospective Studies
;
Infusions, Intra-Arterial
;
Treatment Outcome